The Europe Insulin Pens Market size is estimated at USD 2.13 billion in 2023 and is expected to reach USD 2.29 billion by 2028, growing at a CAGR of 1.45% during the forecast period (2023-2028).
The COVID-19 pandemic has substantially impacted the European Insulin Pens Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers have taken care during COVID-19 to deliver insulin devices to diabetes patients with the help of local governments. Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and maintain normal blood glucose levels, which led to an increase in the usage of insulin pens.
European countries are suffering from the burden of high diabetes expenditure due to its rising prevalence. Approximately 10% of the total diabetes population has type-1 diabetes and approximately out of this 10% of people only 80-90% use Insulin but the usage of insulin is rising from time to time, even type-2 diabetes patients are using insulin drugs during COVID-19.Technological advancements have increased over the period in Insulin Pens.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
According to the IDF 2021 report, about 1 in 11 adults have diabetes in Europe, accounting for approximately 61 million. These figures indicate that approximately 19.6% of global expenditure is spent on diabetes in Europe. Every year about 21,600 children are added to the type-1 diabetic population pool. The European region has witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many daily corrections to maintain nominal blood glucose levels, such as anti-diabetic medication or ingest of additional carbohydrates by monitoring their blood glucose levels.
The government and the companies are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.
Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.
According to IDF, to reduce the diabetes epidemic in the country, the Russian government needs to fully implement a National Diabetes Plan that establishes a state budget that guarantees diabetes care to all Russian citizens. Russia is working towards improving the reimbursement system for all aspects of diabetes care, limiting out-of-pocket payments, and preventing households from incurring catastrophic expenditures. Also, implementing a national screening program to improve the early identification of disturbed carbohydrate metabolism and creating a specialized diabetes health service under the Ministry of Health of the Russian Federation.
Various initiatives have been launched to control diabetes in the country. For instance, in Moscow Urban Forum 2021, a Letter of Intent was signed between the Youth Council under the Moscow Department of Health, Moscow Urban Forum, Moscow Diabetic Association, Moscow Diabetic Association Medical Section, KB Strelka, and Novo Nordisk to implement the Cities Changing Diabetes program in Moscow. The program in Moscow is aimed at a comprehensive assessment of the features of diabetes challenges that are relevant for Moscow and the development of an action plan to combat this disease among the most vulnerable groups of the population.
Over the years, several technological innovations have been developed that have created new types of devices that are much less cumbersome and more comfortable for patients than traditional ones. Such advantages have helped the rise in the adoption of these products in the Russian market.
The COVID-19 pandemic has substantially impacted the European Insulin Pens Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers have taken care during COVID-19 to deliver insulin devices to diabetes patients with the help of local governments. Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and maintain normal blood glucose levels, which led to an increase in the usage of insulin pens.
European countries are suffering from the burden of high diabetes expenditure due to its rising prevalence. Approximately 10% of the total diabetes population has type-1 diabetes and approximately out of this 10% of people only 80-90% use Insulin but the usage of insulin is rising from time to time, even type-2 diabetes patients are using insulin drugs during COVID-19.Technological advancements have increased over the period in Insulin Pens.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Insulin Pens Market Trends
Increasing diabetes prevalence
The diabetes population in the European region is expected to rise by more than 5% over the forecast period.According to the IDF 2021 report, about 1 in 11 adults have diabetes in Europe, accounting for approximately 61 million. These figures indicate that approximately 19.6% of global expenditure is spent on diabetes in Europe. Every year about 21,600 children are added to the type-1 diabetic population pool. The European region has witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many daily corrections to maintain nominal blood glucose levels, such as anti-diabetic medication or ingest of additional carbohydrates by monitoring their blood glucose levels.
The government and the companies are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.
Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.
Russia holds the highest market share in the Europe Insulin Pens Market in the current year
Russia holds the highest market share in the Europe Insulin Pens Market this year and is expected to register a CAGR of more than 0.8% over the forecast period.According to IDF, to reduce the diabetes epidemic in the country, the Russian government needs to fully implement a National Diabetes Plan that establishes a state budget that guarantees diabetes care to all Russian citizens. Russia is working towards improving the reimbursement system for all aspects of diabetes care, limiting out-of-pocket payments, and preventing households from incurring catastrophic expenditures. Also, implementing a national screening program to improve the early identification of disturbed carbohydrate metabolism and creating a specialized diabetes health service under the Ministry of Health of the Russian Federation.
Various initiatives have been launched to control diabetes in the country. For instance, in Moscow Urban Forum 2021, a Letter of Intent was signed between the Youth Council under the Moscow Department of Health, Moscow Urban Forum, Moscow Diabetic Association, Moscow Diabetic Association Medical Section, KB Strelka, and Novo Nordisk to implement the Cities Changing Diabetes program in Moscow. The program in Moscow is aimed at a comprehensive assessment of the features of diabetes challenges that are relevant for Moscow and the development of an action plan to combat this disease among the most vulnerable groups of the population.
Over the years, several technological innovations have been developed that have created new types of devices that are much less cumbersome and more comfortable for patients than traditional ones. Such advantages have helped the rise in the adoption of these products in the Russian market.
Europe Insulin Pens Industry Overview
The Europe Insulin Pens Market is moderately consolidated in nature due to the presence of a few major companies operating globally as well as regionally i.e.Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, etc. among others.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- Sanofi
- Eli Lilly
- Biocon
- Medtronic
- Wockhardt
Methodology
LOADING...
